These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 4609365)
1. Individualization of narcotic analgesic therapy. Rusy BF Med Clin North Am; 1974 Sep; 58(5):1137-41. PubMed ID: 4609365 [No Abstract] [Full Text] [Related]
2. [Main factors of variations in lidocaine pharmacokinetics]. Bruguerolle B; Valli M; Jadot G; Bouyard P Therapie; 1983; 38(1):27-38. PubMed ID: 6346570 [No Abstract] [Full Text] [Related]
3. [On the pathology of storage iron. I. Ferritin and hemosiderin content of human organs in liver, kidney and circulatory diseases]. WOEHLER F; OTTE W; FUELGRAFF M Acta Haematol; 1961 Jun; 25():337-54. PubMed ID: 14007824 [No Abstract] [Full Text] [Related]
4. [The influence of physiopathologic and genetic factors on drug biotransformation]. Orzechowska-Juzwenko K Pol Arch Med Wewn; 1997 Dec; 98(12):561-8. PubMed ID: 9640086 [No Abstract] [Full Text] [Related]
5. [Ionized magnesium: its value in functional pathology]. Dubois F; Tomasini S; Duc ML; Duc M; Belleville F Ann Biol Clin (Paris); 1997; 55(6):639-40. PubMed ID: 9499933 [No Abstract] [Full Text] [Related]
6. [Drug catabolism and its significance for pharmacotherapy]. Kolenda KD Med Klin; 1980 Mar; 75(7):240-50. PubMed ID: 6771507 [No Abstract] [Full Text] [Related]
7. Fibronectin in disease. Akiyama SK; Yamada KM Monogr Pathol; 1983; 24():55-96. PubMed ID: 6350858 [No Abstract] [Full Text] [Related]
8. The disposition and effects of sedatives and analgesics in liver disease. Hoyampa AM; Branch RA; Schenker S Annu Rev Med; 1978; 29():205-18. PubMed ID: 348033 [No Abstract] [Full Text] [Related]
9. Pharmacokinetics of intravenous anaesthetics: implications for clinical use. Ghoneim MM; Korttila K Clin Pharmacokinet; 1977; 2(5):344-72. PubMed ID: 21053 [No Abstract] [Full Text] [Related]
10. Drug-disease interactions: a review of the literature. Gidumal R; Kupersmith J Mt Sinai J Med; 1981; 48(1):7-20. PubMed ID: 7010124 [No Abstract] [Full Text] [Related]
11. Panel report on nutritional support of patients with liver, renal, and cardiopulmonary diseases. Fischer JE; Fishman AP Am J Clin Nutr; 1981 Jun; 34(6 Suppl):1235-45. PubMed ID: 6786086 [No Abstract] [Full Text] [Related]
13. [Utility of atazanavir in special populations]. Antela López A Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():49-54. PubMed ID: 20116618 [TBL] [Abstract][Full Text] [Related]
14. [Useful indications for the use of antibodies]. Held AJ SSO Schweiz Monatsschr Zahnheilkd; 1977 Feb; 87(2):164-7. PubMed ID: 15316 [No Abstract] [Full Text] [Related]
15. The effects of organ dysfunction on drug dosing. Egorin M Clin Adv Hematol Oncol; 2006 Feb; 4(2):116-8. PubMed ID: 16728919 [No Abstract] [Full Text] [Related]
16. [Pharmacokinetics of antihypertensive drugs in kidney and liver diseases]. Knauf H; Mutschler E MMW Munch Med Wochenschr; 1983 Nov; 125(45):1037-40. PubMed ID: 6139750 [No Abstract] [Full Text] [Related]
17. [Biotransformation of drugs by the liver]. González Macias JG Rev Clin Esp; 1974 Nov; 135(3):207-18. PubMed ID: 4615350 [No Abstract] [Full Text] [Related]
18. Individualization of dosage of antiarrhythmic drugs. Kessler KM Med Clin North Am; 1974 Sep; 58(5):1019-26. PubMed ID: 4609363 [No Abstract] [Full Text] [Related]
19. Signaling pathways of prohibitin and its role in diseases. Zhou TB; Qin YH J Recept Signal Transduct Res; 2013; 33(1):28-36. PubMed ID: 23327602 [TBL] [Abstract][Full Text] [Related]